IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v28y2010i7p585-595.html
   My bibliography  Save this article

Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy

Author

Listed:
  • Edward Wilson
  • Erika Sims
  • Stanley Musgrave
  • Lee Shepstone
  • Annie Blyth
  • Jamie Murdoch
  • H. Mugford
  • Elizabeth Juniper
  • Jon Ayres
  • Stephanie Wolfe
  • Daryl Freeman
  • Richard Gilbert
  • Ian Harvey
  • Elizabeth Hillyer
  • David Price

Abstract

Background: Information is lacking on the relative effectiveness and cost effectiveness — in a primary-care setting — of leukotriene receptor antagonists (LTRAs) as an alternative to inhaled corticosteroids (ICS) for initial asthma controller therapy. Objective: To compare the cost effectiveness of LTRAs versus ICS for patients initiating asthma controller therapy. Methods: An economic evaluation was conducted alongside a 2-year, pragmatic, randomized controlled trial set in 53 primary-care practices in the UK. Patients aged 1280 years with asthma and symptoms requiring regular antiinflammatory therapy (n=326) were randomly assigned to LTRAs (n=162) or ICS (n=164). The main outcome measures were the incremental costs per point improvement in the Mini Asthma Quality of Life Questionnaire, per point improvement in the Asthma Control Questionnaire and per QALY gained from the UK NHS and societal perspectives. Results: Over 2 years, resource use was similar between the two treatment groups, but the cost to society per patient was significantly higher for the LTRA group, at £711 versus £433 for the ICS group (adjusted difference £204; 95% CI 74, 308) [year 2005 values]. Cost differences were driven primarily by differences in prescription drug costs, particularly study drug costs. There was a nonsignificant (imputed, adjusted) difference between treatment groups, favouring ICS, in QALYs gained at 2 years of −0.073 (95% CI −0.143, 0.010). Therapy with LTRAs was, on average, a dominated strategy, and, at a threshold for willingness to pay of £30 000 per QALY gained, the probability of LTRAs being cost effective compared with ICS was approximately 3% from both societal and NHS perspectives. Conclusions: There is a very low probability of LTRAs being cost effective in the UK, at 2005 values, compared with ICS for initial asthma controller therapy. Trial registration: UK National Research Register N0547145240; Controlled Clinical Trials ISRCTN99132811. Copyright Adis Data Information BV 2010

Suggested Citation

  • Edward Wilson & Erika Sims & Stanley Musgrave & Lee Shepstone & Annie Blyth & Jamie Murdoch & H. Mugford & Elizabeth Juniper & Jon Ayres & Stephanie Wolfe & Daryl Freeman & Richard Gilbert & Ian Harve, 2010. "Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy," PharmacoEconomics, Springer, vol. 28(7), pages 585-595, July.
    • Handle: RePEc:spr:pharme:v:28:y:2010:i:7:p:585-595
    DOI: 10.2165/11537550-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11537550-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/11537550-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Koopmanschap, Marc A. & Rutten, Frans F. H. & van Ineveld, B. Martin & van Roijen, Leona, 1997. "Reply to Johanneson's and Karlsson's comment," Journal of Health Economics, Elsevier, vol. 16(2), pages 257-259, April.
    2. Drummond, Michael F. & Sculpher, Mark J. & Torrance, George W. & O'Brien, Bernie J. & Stoddart, Greg L., 2005. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 3, number 9780198529453.
    3. Johannesson, Magnus & Karlsson, Goran, 1997. "The friction cost method: A comment," Journal of Health Economics, Elsevier, vol. 16(2), pages 249-255, April.
    4. Koopmanschap, Marc A. & Rutten, Frans F. H. & van Ineveld, B. Martin & van Roijen, Leona, 1995. "The friction cost method for measuring indirect costs of disease," Journal of Health Economics, Elsevier, vol. 14(2), pages 171-189, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Marieke Krol & Werner Brouwer, 2014. "How to Estimate Productivity Costs in Economic Evaluations," PharmacoEconomics, Springer, vol. 32(4), pages 335-344, April.
    2. Werner B.F. Brouwer & Frans F.H. Rutten, 2003. "The missing link: on the line between C and E," Health Economics, John Wiley & Sons, Ltd., vol. 12(8), pages 629-636, August.
    3. Clive Pritchard;Martin Sculpher, 2000. "Productivity Costs: Principles and Practice in Economic Evaluation," Monograph 000464, Office of Health Economics.
    4. Brouwer, Werner B. F. & Koopmanschap, Marc A., 2000. "On the economic foundations of CEA. Ladies and gentlemen, take your positions!," Journal of Health Economics, Elsevier, vol. 19(4), pages 439-459, July.
    5. Anne Tiainen & Clas Rehnberg, 2010. "The Economic Burden of Psychiatric Disorders in Sweden," International Journal of Social Psychiatry, , vol. 56(5), pages 515-526, September.
    6. Mennini, Francesco Saverio & Gitto, Lara, 2022. "Approaches to Estimating Indirect Costs in Healthcare: Motivations for Choice," MPRA Paper 112129, University Library of Munich, Germany.
    7. Berta Rivera & Bruno Casal & Luis Currais, 2017. "Crisis, suicide and labour productivity losses in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(1), pages 83-96, January.
    8. John A. Nyman, 2012. "Productivity Costs Revisited: Toward A New Us Policy," Health Economics, John Wiley & Sons, Ltd., vol. 21(12), pages 1387-1401, December.
    9. Hassan Serrier & Hélène Sultan-Taieb & Danièle Luce & Sophie Bejean, 2014. "Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(6), pages 661-673, July.
    10. Xiaodi Xie & Jürgen Rehrn & Eric Single & Lynda Robson & Josh Paul, 1998. "The economic costs of illicit drug use in Ontario, 1992," Health Economics, John Wiley & Sons, Ltd., vol. 7(1), pages 81-85, February.
    11. Oliver Fritz & Peter Mayerhofer & Reinhard Haller & Gerhard Streicher & Florian Bachner & Herwig Ostermann, 2013. "Die regionalwirtschaftlichen Effekte der österreichischen Krankenanstalten," WIFO Studies, WIFO, number 46672, April.
    12. Henry Zheng & Fred Ehrlich & Janaki Amin, 2010. "Productivity loss resulting from coronary heart disease in Australia," Applied Health Economics and Health Policy, Springer, vol. 8(3), pages 179-189, May.
    13. Ilias Goranitis & Leana Bellanca & Amanda J Daley & Adele Thomas & Helen Stokes-Lampard & Andrea K Roalfe & Sue Jowett, 2017. "Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial," PLOS ONE, Public Library of Science, vol. 12(9), pages 1-15, September.
    14. Marieke Krol & Jocé Papenburg & Marc Koopmanschap & Werner Brouwer, 2011. "Do Productivity Costs Matter?," PharmacoEconomics, Springer, vol. 29(7), pages 601-619, July.
    15. Robin de Vries & Mirjam Kretzschmar & Joop F P Schellekens & Florens G A Versteegh & Tjalke A Westra & John J Roord & Maarten J Postma, 2010. "Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model," PLOS ONE, Public Library of Science, vol. 5(10), pages 1-11, October.
    16. Jonas Steel & Lode Godderis & Jeroen Luyten, 2018. "Methodological Challenges in the Economic Evaluation of Occupational Health and Safety Programmes," IJERPH, MDPI, vol. 15(11), pages 1-12, November.
    17. Berta Rivera & Bruno Casal & Luis Currais, 2015. "The social cost of illegal drug consumption in Spain: identifying and quantifying its elements," Working Papers. Collection B: Regional and sectoral economics 1503, Universidade de Vigo, GEN - Governance and Economics research Network.
    18. Josue Mbonigaba & Wilfred Gbenga Akinola, 2021. "Productivity and Income Effect of Breast Cancer among Women in Southwestern Nigeria," Economies, MDPI, vol. 9(3), pages 1-19, September.
    19. Hanna Gyllensten & Michael Wiberg & Kristina Alexanderson & Anders Norlund & Emilie Friberg & Jan Hillert & Olivia Ernstsson & Petter Tinghög, 2018. "Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 435-446, April.
    20. Juan Oliva & Félix Lobo & Julio López-Bastida & Néboa Zozaya & Rosa Romay, 2005. "Indirect costs of cervical and breast cancers in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(4), pages 309-313, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:28:y:2010:i:7:p:585-595. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.